← Back to Search

The Diagnostic Ultrasound Enthesitis Tool (DUET) Study (DUET Trial)

N/A
Waitlist Available
Led By Lihi Eder, MD, PhD
Research Sponsored by Women's College Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from beginning to end of physical & ultrasound assessment, up to 1.5 hours
Awards & highlights
No Placebo-Only Group

Summary

Psoriatic arthritis (PsA) is a type of joint disease that can lead to severe joint damage and disability within the first few years of the disease. This is why early detection and treatment of the disease is essential to prevent serious joint damage and improve long-term outcomes in these patients. However, there is currently no reliable way to tell the difference between PsA and other types of joint disease. This makes it difficult to detect PsA early. Enthesitis is an inflammation of the area where muscle tendons and ligaments attach to bones. Enthesitis is a key feature in PsA and can be easily detected using ultrasonography. The aim of this research study is to develop a system to evaluate enthesitis using ultrasonography, which can be used as an effective tool in the early detection of PsA. This will help in providing patients with early treatment to prevent further joint damage.

Eligible Conditions
  • Osteoarthritis
  • Psoriasis
  • Psoriatic Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from beginning to end of physical & ultrasound assessment, up to 1.5 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and from beginning to end of physical & ultrasound assessment, up to 1.5 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
DUET scoring system for early diagnosis of PsA
Secondary study objectives
Assess the construct validity of the new DUET scoring system

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Psoriatic ArthritisExperimental Treatment1 Intervention
Subjects newly diagnosed with psoriatic arthritis (\< 5 years), confirmed by a rheumatologist and fulfilling the ClASsification for Psoriatic ARthritis (CASPAR) criteria.
Group II: Psoriasis without musculoskeletal symptomsExperimental Treatment1 Intervention
Patients with dermatologist confirmed psoriasis, without any history of Psoriatic Arthritis, and musculoskeletal symptoms.
Group III: Non-Inflammatory Rheumatic conditionsExperimental Treatment1 Intervention
Patients with non-inflammatory rheumatic conditions such as osteoarthritis, non-specific back pain, soft tissue rheumatism, degenerative tendinopathy and fibromyalgia. Patients with present or past history of psoriasis, psoriatic arthritis, known or suspected rheumatic inflammatory conditions (e.g. rheumatoid arthritis, spondyloarthritis and gout), and/or inflammatory bowel disease will be excluded.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Musculoskeletal Ultrasound
2014
N/A
~440

Find a Location

Who is running the clinical trial?

Women's College HospitalLead Sponsor
106 Previous Clinical Trials
43,142 Total Patients Enrolled
Group for Research and Assessment of Psoriasis and Psoriatic ArthritisNETWORK
2 Previous Clinical Trials
440 Total Patients Enrolled
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)UNKNOWN
1 Previous Clinical Trials
400 Total Patients Enrolled
Lihi Eder, MD, PhDPrincipal InvestigatorUniversity of Toronto
2 Previous Clinical Trials
630 Total Patients Enrolled
Gurjit S Kaeley, MDPrincipal InvestigatorUniversity of Florida
Sibel Z Aydin, MDPrincipal InvestigatorUniversity of Ottawa
~88 spots leftby Jan 2026